Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience (NASDAQ: DARE) reported Q2 2024 financial results and provided a company update. Key highlights include:
1. Ongoing enrollment in the Ovaprene Phase 3 contraceptive efficacy study across the U.S.
2. Progress on Sildenafil Cream, 3.6% for female sexual arousal disorder, awaiting FDA feedback on Phase 3 study design.
3. Cash and cash equivalents of $16.4 million as of June 30, 2024.
4. Q2 2024 R&D expenses decreased 19% to $4.9 million, while G&A expenses decreased to $2.4 million.
5. Received $22 million in April 2024 from a non-dilutive royalty monetization transaction.
The company continues to focus on advancing its late-stage candidates, all representing first-in-category opportunities in women's health.
Daré Bioscience (NASDAQ: DARE), a leader in women's health innovation, has announced its upcoming second quarter 2024 financial results conference call and webcast. The event is scheduled for August 12, 2024, at 4:30 p.m. Eastern Time. The company will release its financial results for the quarter ended June 30, 2024, after market close on the same day. Investors can access the call via phone or live webcast, with dial-in numbers provided for both U.S. and international participants. The conference ID is 6756565. The webcast will be available under the Investors section of Daré's website and will remain accessible for replay until August 26, 2024.
Daré Bioscience (NASDAQ: DARE) has regained compliance with Nasdaq's minimum bid price rule, as announced on July 19, 2024. The company's stock closed at $1.00 or higher for 10 consecutive trading sessions, meeting the Nasdaq Listing Rule 5550(a)(2) requirement. CEO Sabrina Martucci Johnson expressed enthusiasm about this development, stating it strengthens the company's market position and enhances its ability to advance its vision.
Johnson also provided updates on key programs in Daré's portfolio:
- Ongoing enrollment in the pivotal Phase 3 study of Ovaprene®, a potential first-in-category hormone-free monthly intravaginal contraceptive
- Continued activities supporting progression toward a Phase 3 trial of Sildenafil Cream, 3.6% for female sexual arousal disorder, an area with no current FDA-approved treatments
The company remains focused on accelerating the development of innovative treatments for women's health, with an emphasis on first-in-category opportunities.
Daré Bioscience (NASDAQ: DARE) will implement a 1-for-12 reverse stock split of its common shares effective July 1, 2024. This action aims to elevate the stock's bid price to meet Nasdaq's $1.00 minimum bid price requirement. Authorized by shareholders on June 5, 2024, the reverse split will reduce the total number of outstanding shares from about 101.1 million to 8.4 million, while also adjusting the exercise prices and number of shares underlying stock options and warrants. No fractional shares will be issued; instead, fractional interests will be rounded up. The stock will continue trading under the symbol 'DARE' with a new CUSIP number 23666P200.
Daré Bioscience (NASDAQ: DARE) published the efficacy results of their Phase 2b study on topical Sildenafil Cream, 3.6% for treating Female Sexual Arousal Disorder (FSAD) in the journal Obstetrics & Gynecology. This double-blind, placebo-controlled study showed significant improvements in sexual arousal sensation, reduced sexual distress, and increased desire and orgasm, particularly in a subset of women with FSAD, with or without decreased desire. Currently, no FDA-approved therapies exist for FSAD. Daré had a positive end-of-Phase 2 meeting with the FDA and awaits feedback on proposed endpoints for Phase 3 trials, which is expected this quarter.
Daré Bioscience (NASDAQ: DARE) reported its Q1 2024 financials and company updates. Key developments include the ongoing Phase 3 study of Ovaprene®, a hormone-free contraceptive, and the successful end-of-Phase 2 meeting with the FDA for Sildenafil Cream, aimed at treating female sexual arousal disorder. Financial highlights show a decrease in Q1 2024 R&D expenses to $3.3 million from $5.0 million in Q1 2023, and a $22 million non-dilutive financing deal secured in April 2024. Cash reserves stood at $3.6 million as of March 31, 2024. The company's collaboration with Organon on XACIATO™ continues, with further milestones anticipated in 2024.
Daré Bioscience, Inc. will host a conference call and webcast on May 14, 2024, to discuss its financial results for Q1 2024. The company is a leader in women's health innovation, with details on how to access the call provided in the press release.
Daré Bioscience, Inc. (NASDAQ: DARE) has been chosen as a spoke member of the Investor Catalyst Hub, part of the nationwide ARPA-H network. This selection provides Daré with access to funding, networking opportunities, and the ability to influence research priorities in women's health.
Daré Bioscience secured $22 million in non-dilutive strategic royalty financing to advance Phase 3 first-in-category women’s health product candidates through key catalysts. The transaction with XOMA provides significant capital for Daré to focus on advancing Ovaprene® and Sildenafil Cream, 3.6%. This accelerates potential cash flows and shareholder value, showcasing the company's commitment to delivering value for all stakeholders.
Summary not available.